Health Canada approves Moderna’s mRNA RSV vaccine, company says
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update. Strengthened Cash, Strategic Refocus and Pipeline Progress De ...
Hosted on MSN6d
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...
pharmaphorum3d
GSK turns its guns on Moderna in mRNA jab patent dispute
GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...
pharmaphorum6d
mRNA technologies: Looking beyond COVID vaccines
Several pharma companies – Arcturus Therapeutics, Bayer, GSK, Moderna, Pfizer, and Sanofi - are all racing to develop mRNA influenza vaccines. GSK has teamed up with CureVac and currently has ...
The Globe and Mail6d
Health Canada approves Moderna’s mRNA RSV vaccine, company says
Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory ... Arexvy, manufactured by GSK, and Abrysvo, made by Pfizer. Earlier this year, the National Advisory Committee ...